Consequently, grade 2 and 3 glioma patients with EGFR amplification (copy number fold change > 1.2, n = 103) had higher level of TAM-SPP1 (p < 0.0001) as well as higher score of TAM-SPP1 marker genes compared to patients without EGFR amplification (Fig. 7d, e). The gene discussed is SPP1; the disease is central nervous system cancer.